Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

por Dere, Randall C., Beardsley, Richard L., Lu, Dan, Lu, Tong, Ku, Grace H-W., Man, Gabriel, Nguyen, Van, Kaur, Surinder
Publicado 2023

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

por Shemesh, Colby S., Agarwal, Priya, Lu, Tong, Lee, Calvin, Dere, Randall C., Li, Xiaobin, Li, Chunze, Jin, Jin Y., Girish, Sandhya, Miles, Dale, Lu, Dan
Publicado 2020

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys

por Lu, Dan, Jin, Jin Yan, Girish, Sandhya, Agarwal, Priya, Li, Dongwei, Prabhu, Saileta, Dere, Randall C., Saad, Ola M., Nazzal, Denise, Koppada, Neelima, Ramanujan, Saroja, Ng, Chee M.
Publicado 2014

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

por Lu, Dan, Lu, Tong, Gibiansky, Leonid, Li, Xiaobin, Li, Chunze, Agarwal, Priya, Shemesh, Colby S., Shi, Rong, Dere, Randall C., Hirata, Jamie, Miles, Dale, Chanu, Pascal, Girish, Sandhya, Jin, Jin Yan
Publicado 2019

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in...

por Lu, Dan, Lu, Tong, Shi, Rong, Gibiansky, Leonid, Agarwal, Priya, Shemesh, Colby S., Dere, Randall C., Ogbu, Uzor, Hirata, Jamie, Chanu, Pascal, Girish, Sandhya, Jin, Jin Yan, Li, Chunze, Miles, Dale
Publicado 2020

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells

por Fuh, Franklin K, Looney, Caroline, Li, Dongwei, Poon, Kirsten A, Dere, Randall C, Danilenko, Dimitry M, McBride, Jacqueline, Reed, Chae, Chung, Shan, Zheng, Bing, Mathews, William Rodney, Polson, Andrew, Prabhu, Saileta, Williams, Marna
Publicado 2017

A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia

por Daver, Naval, Salhotra, Amandeep, Brandwein, Joseph M., Podoltsev, Nikolai A., Pollyea, Daniel A., Jurcic, Joseph G., Assouline, Sarit, Yee, Karen, Li, Mengsong, Pourmohamad, Tony, Samineni, Divya, Sumiyoshi, Teiko, Vaze, Anjali, Dere, Randall C., Ma, Connie, Cooper, James
Publicado 2021

Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin

por Li, Dongwei, Lee, Donna, Dere, Randall C., Zheng, Bing, Yu, Shang‐Fan, Fuh, Franklin K., Kozak, Katherine R., Chung, Shan, Bumbaca Yadav, Daniela, Nazzal, Denise, Danilenko, Dimitry, Go, Mary Ann T., Williams, Marna, Polson, Andrew G., Poon, Kirsten Achilles, Prabhu, Saileta
Publicado 2019

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia

por Leipold, Douglas D., Figueroa, Isabel, Masih, Shabkhaiz, Latifi, Brandon, Yip, Victor, Shen, Ben-Quan, Dere, Randall C., Carrasco-Triguero, Montserrat, Lee, M. Violet, Saad, Ola M., Liu, Luna, He, Jintang, Su, Dian, Xu, Keyang, Vuillemenot, Brian R., Laing, Steven T., Schutten, Melissa, Kozak, Katherine R., Zheng, Bing, Polson, Andrew G., Kamath, Amrita V.
Publicado 2018